154 related articles for article (PubMed ID: 23856830)
1. Amyloid PET/MRI in the differential diagnosis of dementia.
Vercher-Conejero JL; Rubbert C; Kohan AA; Partovi S; O'Donnell JK
Clin Nucl Med; 2014 Jun; 39(6):e336-9. PubMed ID: 23856830
[TBL] [Abstract][Full Text] [Related]
2. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
3. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
4. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.
Mitsis EM; Bender HA; Kostakoglu L; Machac J; Martin J; Woehr JL; Sewell MC; Aloysi A; Goldstein MA; Li C; Sano M; Gandy S
Mol Neurodegener; 2014 Feb; 9():10. PubMed ID: 24484858
[TBL] [Abstract][Full Text] [Related]
5. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
6. Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.
Degenhardt EK; Witte MM; Case MG; Yu P; Henley DB; Hochstetler HM; D'Souza DN; Trzepacz PT
Psychosomatics; 2016; 57(2):208-16. PubMed ID: 26892326
[TBL] [Abstract][Full Text] [Related]
7. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
8. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.
Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ
Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654
[TBL] [Abstract][Full Text] [Related]
9. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
10. Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies.
Donaghy PC; Firbank MJ; Thomas AJ; Lloyd J; Petrides G; Barnett N; Olsen K; O'Brien JT
Mov Disord; 2018 Jul; 33(7):1130-1138. PubMed ID: 29672930
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
Pontecorvo MJ; Siderowf A; Dubois B; Doraiswamy PM; Frisoni GB; Grundman M; Nobili F; Sadowsky CH; Salloway S; Arora AK; Chevrette A; Deberdt W; Dell'Agnello G; Flitter M; Galante N; Lowrey MJ; Lu M; McGeehan A; Devous MD; Mintun MA
Dement Geriatr Cogn Disord; 2017; 44(3-4):129-143. PubMed ID: 28787712
[TBL] [Abstract][Full Text] [Related]
12. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
Yang L; Rieves D; Ganley C
N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
[No Abstract] [Full Text] [Related]
13. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L; Newell M; Devous MD
J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
[TBL] [Abstract][Full Text] [Related]
14. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
15. Patient Requests for Off-Label Bioprediction of Dementia.
Baum ML
Camb Q Healthc Ethics; 2016 Oct; 25(4):686-90. PubMed ID: 27634719
[TBL] [Abstract][Full Text] [Related]
16. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
17. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.
Sabbagh MN; Chen K; Rogers J; Fleisher AS; Liebsack C; Bandy D; Belden C; Protas H; Thiyyagura P; Liu X; Roontiva A; Luo J; Jacobson S; Malek-Ahmadi M; Powell J; Reiman EM
Alzheimers Dement; 2015 Aug; 11(8):994-1004. PubMed ID: 25849033
[TBL] [Abstract][Full Text] [Related]
18. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
Bensaïdane MR; Beauregard JM; Poulin S; Buteau FA; Guimond J; Bergeron D; Verret L; Fortin MP; Houde M; Bouchard RW; Soucy JP; Laforce R
J Alzheimers Dis; 2016 Apr; 52(4):1251-62. PubMed ID: 27104896
[TBL] [Abstract][Full Text] [Related]
20. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
